Live
FierceBiotechKailera plots IPO to fund obesity pipeline after one of the biggest raises of 2025FierceBiotechBiogen’s litifilimab sparkles in midphase lupus trial, raising hopes for pivotal readoutFierceBiotechKardigan hypertension drug tangles biomarker win with blood pressure miss in phase 2 trialEndpoints News#AAD26: Sanofi reports underwhelming Phase 3 OX40 data in eczema, second case of Kaposi’s sarcomaThermo FisherThermo Fisher (TMO) Shares Up Since Jim Cramer Called the Firm “Unbelievable” - Insider MonkeyAgilentAgilent Technologies' Advanced Chromatography Solutions: Driving Precision Analytics in North Americ - AD HOC NEWSBioPharma DiveTrustworthy AI in clinical oversightLonza NewsLonza Group AG Stock: A Key Player in Biopharma Contract Manufacturing for North American Investors - AD HOC NEWSFierceBiotechPredicting Clinical Seizure Liability Earlier in Drug DevelopmentFierceBiotechScaling Radioligand Therapy: Expanding the Impact of TheranosticsFierceBiotechLilly further embraces Insilico’s AI tech, inking R&D collab worth up to $2.75BEndpoints NewsKailera plans IPO for Phase 3 obesity drug from Hengrui
FierceBiotech Mar 30, 2026

Kailera plots IPO to fund obesity pipeline after one of the biggest raises of 2025

Kailera plots IPO to fund obesity pipeline after one of the biggest raises of 2025

Original
Body unavailable. Use the original source.

Directory

59 All